drugset

drugset / Trial / NCT00181155

Intravenous Allopurinol in Heart Failure

NCT00181155 ↗

Phase 2 Completed 18 enrolled Johns Hopkins University National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

Timeline

Start: 2004-11
Primary completion: 2010-12
Completion: 2010-12

Publications

Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012 Feb 28;59(9):802-8. doi: 10.1016/j.jacc.2011.10.895.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allopurinol	Small molecule	300 mg	Intravenous

Indications